Merck

FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
BioPharma Dive
AstraZeneca
Merck
Lynparza
prostate cancer
FDA
Flag link:
Merck study: mRNA technology a ‘game changer’ for Asia-Pacific vaccine manufacturers
Merck study: mRNA technology a ‘game changer’ for Asia-Pacific vaccine manufacturers
Biopharma Reporter
vaccines
MRNA
Merck
Asia-Pacific
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
Merck and Eisai tease results for renal carcinoma treatment
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Merck
Eisai
ASCO 2023
Lenvima
Keytruda
renal cell carcinoma
Flag link:
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
BioPharma Dive
ASCO 2023
antibody-drug conjugate
Merck
BioNTech
Daiichi Sankyo
Flag link:
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?
Fierce Pharma
ASCO 2023
Merck
Keytruda
cervical cancer
Flag link:
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
Fierce Pharma
ASCO 2023
Merck
Keytruda
Novartis
Kisqali
non-small cell lung cancer
early breast cancer
Flag link:
Merck’s Gardasil Under Legal Scrutiny Despite Lack of Evidence to Support Suits
Merck’s Gardasil Under Legal Scrutiny Despite Lack of Evidence to Support Suits
BioSpace
Merck
vaccines
Gardasil
legal
HPV
side effects
Flag link:
Investigation raises questions over lack of 'substantial evidence' for FDA approved antibiotic
Investigation raises questions over lack of 'substantial evidence' for FDA approved antibiotic
Medical Xpress
Merck
antibiotics
Recarbrio
FDA
BMJ
Flag link:
Heightened US antitrust fears rattle biopharma
Heightened US antitrust fears rattle biopharma
EP Vantage
M&A
antitrust
Amgen
Astellas
Bellus Health
Globus Medical
GSK
Horizon Therapeutics
Merck
NuVasive
Pfizer
Prometheus Biosciences
Seagen
Flag link:
Hummingbird and Merck to evaluate combination therapy for NSCLC
Hummingbird and Merck to evaluate combination therapy for NSCLC
Clinical Trials Arena
Merck
Hummingbird Bioscience
HMBD-001
cetuxumab
squamous non-small cell lung cancer
Flag link:
The waxing and waning of the speedy approval
The waxing and waning of the speedy approval
EP Vantage
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Flag link:
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Flag link:
Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival
Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival
Fierce Biotech
Gossamer Bio
layoffs
seralutinib
Merck
PAH
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
Biopharma Bets Big on Antibody-Drug Conjugates
Biopharma Bets Big on Antibody-Drug Conjugates
BioSpace
antibody-drug conjugate
Merck
Seagen
M&A
AstraZeneca
BioNTech
Bristol Myers Squibb
Flag link:
Merck bets big on PRA023 with $10.8bn Prometheus acquisition offer
Merck bets big on PRA023 with $10.8bn Prometheus acquisition offer
Clinical Trials Arena
Merck
Prometheus Biosciences
PRA023
ulcerative colitis
Flag link:
Merck entitled to $1.4B in cyberattack case after court rejects insurers' 'warlike action' claim
Merck entitled to $1.4B in cyberattack case after court rejects insurers' 'warlike action' claim
Fierce Pharma
Merck
legal
cybersecurity
cyberattacks
Flag link:
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
Crain's Chicago Business
Merck
Prometheus Biosciences
M&A
AbbVie
Bristol Myers Squibb
Flag link:
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
metastatic castration-resistant prostate cancer
Flag link:

Pages